Browse Category

Pharmaceuticals 5 January 2026 - 7 January 2026

Merck stock in focus after CDC rewrites childhood vaccine schedule, puts Gardasil dosing under a microscope

Merck & Co. shares rose 1.3% to $108.87 on Tuesday, after U.S. health officials overhauled the childhood immunization schedule and shifted several vaccines away from broad, routine recommendations.

7 January 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface

Eli Lilly and Company stock closed up 2.2% on Tuesday and was up about 0.1% in after-hours trading after Nimbus Therapeutics said it struck a research and licensing deal with the drugmaker to pursue an oral obesity treatment. Yahoo Finance

7 January 2026

NYSE:LLY·Pharmaceuticals

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Merck & Co shares rose about 1.1% to $108.60 in afternoon trading on Tuesday and earlier hit a 52-week high of $110.16. The broader S&P 500 and the Health Care Select Sector SPDR Fund were also higher.

6 January 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

Johnson & Johnson shares rose on Tuesday after the company reported positive mid-stage data for its experimental lupus drug nipocalimab and outlined plans for late-stage testing. The stock was up $1.10, or 0.5%, at $205.41 in midday New York trading.

6 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next

AbbVie shares rose about 0.5% to $221.18 in midday trading on Tuesday after the drugmaker said Health Canada approved its hepatitis C therapy Maviret for acute and chronic infections.

6 January 2026

NYSE:ABBV·Pharmaceuticals

Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

Shares of Moderna Inc were up 10.7% at $35.60 in midday trading on Tuesday after BofA Global Research raised its price objective on the vaccine maker. The stock touched a session high of $36.25. Reuters

6 January 2026

NASDAQ:MRNA·Pharmaceuticals·Stock Market

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Arrowhead Pharmaceuticals shares rose about 16% on Tuesday after early clinical data showed its experimental gene-silencing obesity drug boosted weight loss when used alongside Eli Lilly’s tirzepatide, sold as Zepbound. The stock was up 16% at $74.13 in midday trading, after swinging between $62.17 and $76.32. Investors.com

6 January 2026

Biotechnology·NASDAQ:ARWR·NYSE:LLY·Pharmaceuticals

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Eli Lilly and Company shares rose about 1.6% on Tuesday after Nimbus Therapeutics announced a research and licensing agreement with the drugmaker aimed at developing an oral obesity treatment. Lilly was trading at $1,057.80 in New York morning trade, after moving between $1,040.15 and $1,070.77 earlier in the session. Reuters

6 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk A/S shares listed in New York as ADRs climbed about 4.7% to $57.71 on Tuesday, after touching an intraday high of $58.14.

6 January 2026

Health News·NYSE:NVO·Pharmaceuticals·Stock Market

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

Alumis Inc shares jumped about 129% in early trade on Tuesday after the drugmaker reported positive late-stage data for its psoriasis pill, envudeucitinib. The stock was at $19.04, up from a previous close of $8.31, after touching $22.30 to set a new 52-week high, Google Finance data showed. Google

6 January 2026

NASDAQ:ALMS·Pharmaceuticals·Stock Market

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie shares were flat in premarket trading on Tuesday after the drugmaker said Health Canada had approved its hepatitis C pill Maviret for both acute and chronic infection. AbbVie stock last traded at $220.18.

6 January 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading on Tuesday, extending gains after the Danish drugmaker began selling its once-daily Wegovy weight-loss pill in the United States. The stock was up at $57.29, compared with a prior close of $55.11. Public

6 January 2026

Health News·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

Pfizer said it will webcast a discussion with Chief Executive Albert Bourla at the J.P. Morgan Healthcare Conference next week, putting the drugmaker’s 2026 reset back in focus. Pfizer shares finished Monday little changed, down 0.04% at $25.17. Pfizer

6 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

Merck & Co shares dipped in late trading on Monday after U.S. health officials rewrote the childhood and adolescent immunization schedule, including a change to a one-dose recommendation for the human papillomavirus vaccine. Merck closed up 0.93% at $107.44 and was last down 0.22% at $107.20 after the bell. Yahoo Finance

6 January 2026

Health News·NYSE:MRK·Pharmaceuticals·Stock Market

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie Inc shares closed down 4% on Monday at $220.18, lagging a Wall Street rally that pushed the Dow to a record high.

6 January 2026

NASDAQ:AMGN·NYSE:ABBV·NYSE:JNJ·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Eli Lilly and Co shares fell on Monday and were last down 3.6% at $1,041.51 in after-hours trading. The stock weakened as rival Novo Nordisk began rolling out a pill version of its Wegovy weight-loss drug in the United States. The Washington Post

6 January 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

Merck & Co shares edged up on Monday as investors looked ahead to the drugmaker’s appearance at the annual J.P. Morgan Healthcare Conference next week. The stock was up 0.3% at $106.80 at 3:35 p.m. EST, after earlier reaching $108.30.

5 January 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Xenon Pharmaceuticals Inc shares were down 6.5% at $41.60 in afternoon trading on Monday, about 8% off the session high. The Nasdaq-listed biotech traded between $45.21 and $41.45, with roughly 787,000 shares changing hands.

5 January 2026

NASDAQ:XENE·Pharmaceuticals·Stock Market

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.

5 January 2026

Health News·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.

5 January 2026

NASDAQ:STTX·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Previous 1 … 25 26 27 28 29 … 47 Next

Pharmaceuticals 5 January 2026 - 7 January 2026

Merck stock in focus after CDC rewrites childhood vaccine schedule, puts Gardasil dosing under a microscope

Eli Lilly stock rises after hours on Nimbus obesity pill deal as Ventyx talks surface

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Johnson & Johnson stock ticks up on lupus drug data as earnings loom

AbbVie stock nudges higher after Canada clears Maviret — what ABBV investors watch next

Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus

Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss

Eli Lilly stock rises on Nimbus obesity pill pact as oral drug race heats up

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Pfizer stock in the spotlight: what to watch ahead of CEO Bourla’s JPM Healthcare Conference webcast

Merck stock dips after CDC vaccine overhaul puts Gardasil dosing in the spotlight

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. market and revives price pressure fears

Merck stock ticks higher as MRK nears recent highs ahead of JPM Healthcare Conference

Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

TechStock² Updates

Ondas stock (ONDS) steady with $406 million H2 revenue milestone ahead

Archer Stock (ACHR) Drops 8% with Boeing Agreement Adding Revenue and Causing Dilution

Humana stock (HUM) climbs 3% as 2027 COLA calculations obscure rising medical-cost shortfall

Marex stock (MRX) surges 13% on trading income fueling 98% revenue growth

SpaceX stock (SPCX) climbs 4% as $74 billion advance surpasses Cursor price

Top Stock Picks

AerCap

Uber

Taiwan Semiconductor

AIG

Ferguson

Live updates

Investment Disclaimer